Navigation Links
Expanding drug development horizons: Receptor behaviors observed in living cell membranes
Date:2/16/2011

Kyoto, Japan -- Unprecedented single molecule imaging movies of living cell membranes, taken by a research team based at Kyoto University and the University of New Mexico, have clarified a decades-old enigma surrounding receptor molecule behaviors. The results, appearing in the latest issue of the Journal of Cell Biology, promise to open the door to new possibilities for drug development.

The work focuses on G protein-coupled receptors (GPCRs), a class of molecules in cell membranes that comprise the largest superfamily in the human genome. In spite of being the focus of roughly half of modern drug development due to their key role in signaling across the membrane, until now it has not been well understood how GPCRs relay signals from the outside world into cells' interiors.

For over 15 years, debate regarding GPCRs' signaling mechanisms has centered on whether these molecules work alone (as monomers) or in pairs (dimers). Using formyl-peptide receptors (FPRs) as a model GPCR, the research team found that the two views are both partially correct.

"By developing a super-quantitation single-molecule imaging method, in which GPCR molecules are inspected one by one in living cell membranes," explained Rinshi Kasai of Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) and lead author of the paper, "we are now able to actually 'see' that each individual FPR molecule moves around in the cell membrane, endlessly interconverting between monomers and dimers with different partners, completing each cycle within a quarter of a second."

According to iCeMS Professor Akihiro Kusumi, "We obtained a parameter called the dissociation constant, which will allow us to predict numbers of monomers and dimers if the total number of GPCRs in a cell is known. The ability of scientists to obtain such key numbers will be essential for understanding GPCR signaling, as well as defects leading to diseases from the neuronal to the immune systems. The implications for drug design, blocking signal amplification by monomer-dimer interconversion, are profoundly important."

The research team, funded in part by the Japan Science and Technology Agency (JST) and the Japanese education ministry MEXT, anticipates that their findings will have a broad impact on the further study of signal transduction in the cell membrane and conceptual and methodological development for drug discovery.


'/>"/>

Contact: Yutaka Iijima
yutaka-iijima@icems.kyoto-u.ac.jp
Institute for Integrated Cell-Material Sciences, Kyoto University
Source:Eurekalert

Related biology technology :

1. Expanding drug development horizons: Receptor behaviors observed in living cell membranes
2. Safe and Secure TV Channel Expanding Programming and Revenue Agreements for 2011 with Pentagons Military News Channel and other Security Industry Leaders
3. Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market
4. San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry
5. No Economic Slowdown for Expanding U.S. Medical Manufacturer
6. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
7. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
8. Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore
9. Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe
10. Rapidly Expanding Ohio Bioscience Industry Drives New Workforce Training Program
11. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):